Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Glucocorticoid-induced bone loss (GIBL) remains a major clinical challenge, manifested by both systemic osteopenia and osteonecrosis of the femoral head under chronic glucocorticoid exposure, yet current therapies are limited in coordinately addressing bone deterioration and vascular impairment. With advances in precision medicine, oligonucleotide therapeutics offer opportunities for pathophysiology-informed intervention.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
